Grupos de investigación

  1. Portada
  2. Publicaciones
  3. Publicaciones 2013-2015

Publicaciones 2013-2015

Publicaciones anteriores

 

  1. "Th17 polarization of memory Th cells in early arthritis: the vasoactive intestinal peptide effect". Jimeno R, Leceta J, Garín M, Ortiz AM, Mellado M, Rodríguez-Frade JM, Martínez C, Pérez-García S, Gomariz RP, Juarranz Y. J Leukoc Biol. 2015 Aug;98(2):257-69. 
  2. "Vasoactive Intestinal Peptide in Early Spondyloarthritis:Low Serum Levels as a Potencial Biomarker for Disease Severity". Seoane IV, Tomero E, Martínez C, García-Vicuña R, Juarranz Y, Lamana A, Ocón E, Ortiz AM, Gómez-León N, González-Álvaro I, Gomariz RP. J Mol Neurosci. 2015 Jul;56(3):577-84. PDF
  3. "The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP". Jimeno R, Gomariz RP, Garín M, Gutiérrez-Cañas I, González-Álvaro I, Carrión, M, Galindo M, Leceta J, Juarranz Y. J Mol Med. 2015 Apr;93(4):457-67. PDF
  4. "Biomarkers predicting a need for intensive treatments in patients with early arthritis". González-Álvaro I, Ortiz AM, Seoane IV, García-Vicuña R, Martínez C, Gomariz RP. Curr Pharm Des. 2015;21(2):170-81.
  5. "Thematic issue: optimizing treatment in rheumatoid arthritis". Gomariz RP, Gonzalez-Alvaro I. Curr Pharm Des. 2015;21(2):129
  6. "Vasoactive intestinal peptide maintains the nonpathogenic profile of human Th17-polarized cells". Jimeno R, Leceta J, Martínez C, Gutiérrez-Cañas I, Carrión M, Pérez-García S, Garín M, Mellado M, Gomariz RP, Juarranz Y. J Mol Neurosci. 2014 Nov;54(3):512-25.
  7. “Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis”. Martínez C, Ortiz AM, Juarranz Y, Lamana A, Seoane IV, Leceta J, García-Vicuña R, Gomariz RP, González-Álvaro I. PLoS One. 2014 Jan 7;9(1):e85248. PDF
  8. “Urokinase plasminogen activator system in synovial fibroblasts from osteoarthritis patients: modulation by inflammatory mediators and neuropeptides”.Pérez-García S, Carrión M, Jimeno R, Ortiz AM, González-Álvaro I, Fernández J, Gomariz RP, Juarranz Y. J Mol Neurosci. 2014 Jan;52(1):18-27.
  9. "VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction”. Carrión M, Juarranz Y, Seoane IV, Martínez C, González-Álvaro I, Pablos JL, Gutiérrez-Cañas I, Gomariz RP. J Mol Neurosci. 2014 Jan;52(1):10-7.
  10. "Growth hormone prevents the development of autoimmune diabetes”.Villares R, Kakabadse D, Juarranz Y, Gomariz RP, Martínez-A C, Mellado M. Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):E4619-27.
  11. “IL-22/IL-22R1 axis and S100A8/A9 alarmins in human osteoarthritic and rheumatoid arthritis synovial fibroblasts”. Carrión M, Juarranz Y, Martínez C, González-Álvaro I, Pablos JL, Gutiérrez-Cañas I, Gomariz RP. Rheumatology (Oxford). 2013 Dec;52(12):2177-86.
  12. “Inflammatory mediators alter interleukin-17 receptor, interleukin-12 and -23 expression in human osteoarthritic and rheumatoid arthritis synovial fibroblasts: immunomodulation by vasoactive intestinal Peptide”. Carrión M, Pérez-García S, Jimeno R, Juarranz Y, González-Álvaro I, Pablos JL, Gutiérrez-Cañas I, Gomariz RP. Neuroimmunomodulation. 2013;20(5):274-84.
  13. “Janus kinases 1 and 2 regulate chemokine-mediated integrin activation and naïve T-cell homing”. Pérez-Rivero G, Cascio G, Soriano SF, Sanz ÁG, de Guinoa JS, Rodríguez-Frade JM, Gomariz RP, Holgado BL, Cabañas C, Carrasco YR, Stein JV, Mellado M. Eur J Immunol. 2013 Jul;43(7):1745-57.